uniQure N.V. (QURE) Getting Somewhat Positive News Coverage, Study Finds
News articles about uniQure N.V. (NASDAQ:QURE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. uniQure N.V. earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.9844930577563 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Leerink Swann Research Analysts Increase Earnings Estimates for uniQure N.V. (QURE) (americanbankingnews.com)
- uniQure N.V. (QURE) vs. The Competition Critical Comparison (americanbankingnews.com)
- uniQure N.V. (QURE) Price Target Raised to $26.00 (americanbankingnews.com)
- uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 (finance.yahoo.com)
- uniQure N.V. (QURE) Downgraded by Zacks Investment Research (americanbankingnews.com)
uniQure N.V. (NASDAQ QURE) traded up $0.18 during midday trading on Monday, reaching $15.89. 221,500 shares of the company’s stock were exchanged, compared to its average volume of 300,871. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73. uniQure N.V. has a one year low of $4.72 and a one year high of $21.35.
Several equities research analysts recently commented on QURE shares. Zacks Investment Research lowered shares of uniQure N.V. from a “buy” rating to a “hold” rating in a research note on Thursday, August 24th. Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the stock a “buy” rating in a research note on Sunday, July 23rd. Leerink Swann lifted their price objective on shares of uniQure N.V. from $19.00 to $26.00 in a research note on Tuesday, November 7th. Evercore ISI started coverage on shares of uniQure N.V. in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 price objective on the stock. Finally, ValuEngine lowered shares of uniQure N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. uniQure N.V. currently has a consensus rating of “Buy” and an average price target of $17.43.
TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/11/13/uniqure-n-v-qure-getting-somewhat-positive-news-coverage-study-finds.html.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.